HIT Company Profile and Key Details

Health In Tech, Inc. (NASDAQ:HIT) closed at $1.62 USD, gaining $0.20 (14.08%) from the previous close of $1.42. The stock is currently mid-range between its 52-week high and low $0.51 and $7.59. With a market capitalization of about $92.19 million, Health In Tech, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~7.96). Key stats such as the average daily volume over the past year has been around 315.75 thousand shares, in line with its 52-week average. Headquartered in Stuart, FL, Health In Tech, Inc. operates in the Technology sector and the Software - Application industry. Led by CEO Tim Johnson, the company employs approximately 73 people and listed since December 23, 2024. Health In Tech, Inc. operates as an insurance technology platform company.

HIT has shown weak momentum, losing -13.66% over the past week and -53.97% over the past quarter, though year-to-date performance is down -12.58%. Short-term trend indicators are bullishly aligned (SMA20 19.62%, SMA50 0.51%, SMA200 -26.09%). The stock’s 14-day RSI is 60.28 (firm momentum), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -82.21% below its high and over 163.67% above its low. Average 10-day trading volume of 111.88 thousand shares is below the 3-month average of 323.63 thousand, indicating normal recent market interest.

Wall Street analysts project EPS growth of 166.84% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $2.50 to $2.50. The high target offers 76.06% upside. The low target suggests 76.06% downside. The mean target is $2.50. This offers 76.06% upside. Health In Tech, Inc. earnings surprise history is a mixed track record. The quarter that ended November 10, 2025, missed forecasts by 0.0%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -50.0% in April 14, 2025.

Health In Tech, Inc. has 44.69 million shares outstanding. The public float is 13.29 million shares, elevated short interest at 1.03% of float. This equals 144.15 thousand shares. The short ratio is 0.09 days. Institutional investors hold 2.77% of the float. Insiders own 70.3%.

Health In Tech, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.15. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that Health In Tech, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.34%, with price expected at $1.51 by March 17, 2026, within a range of $1.42 to $1.60 3-Month Outlook: Projected fall of -90.14%, reaching $0.14 by June 01, 2026, with a range of $0.07 to $0.21. 1-Year Outlook: Projected gain of 17.61%, with price at $1.67 by March 03, 2027, within a range of $1.63 to $1.71.

Health In Tech, Inc. (NASDAQ:HIT) shares are down -12.58% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Health In Tech, Inc. trading at a premium to the broader market with a P/E of 55.95. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $2.50, suggesting 76.06% upside. Our AI forecast model points to short-term strength (6.34% over two weeks), a medium-term fall (-90.14% over three months), and a longer-term gain (17.61% over one year), with expected trading ranges indicating moderate volatility.

Health In Tech, Inc. trades at a P/E ratio of 55.95, slightly above the S&P 500 average, with a price-to-sales ratio of 2.64 and a price-to-book ratio of 4.69 trading at moderately above to book value. The P/FCF stands at 52.47, also above market averages.